Predictive impact of RNF43 mutation (mut) in patients (pts) with pMMR/MSS BRAF V600E mutated metastatic colorectal cancer (mCRC) treated with target therapy (TT) or chemotherapy (CT)

被引：0
|
作者：
Germani, Marco Maria
Moretto, Roberto
Montana, Javier Ros
Intini, Rossana
Ghelardi, Filippo
Vetere, Guglielmo
Toledo, Rodrigo De Almeida
Bergamo, Francesca
Randon, Giovanni
Elez, Elena
Lonardi, Sara
Oldani, Simone
Giordano, Mirella
Rossini, Daniele
Bravo, Walter Ferrari
Ricagno, Gianmarco
Ugolini, Paola Vignali Clara
Fontanini, Gabriella
Cremolini, Chiara
机构：
[1] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[2] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy
[3] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy
[4] Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[5] IRCCS, Dept Oncol, Med Oncol 1, Veneto Inst Oncol IOV, Padua, Italy
[6] Fdn IRCCS Ist Nazl Tumori Milano, Dept Med Oncol, Milan, Italy
[7] Vall dHebron Univ Hosp, Barcelona, Spain
[8] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[9] Univ Pisa, Dept Surg Med Mol Pathol & Crit Area, Pisa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3569
引用
收藏
页数：1
相关论文
共 50 条
  • [41] BRAF V600E Mutation as a Predictive Factor of Anti-EGFR Monoclonal Antibodies Therapeutic Effects in Metastatic Colorectal Cancer: a Meta-analysis
    Qi Wang
    Wei-guo Hu
    Qi-bin Song
    Jia Wei
    Chinese Medical Sciences Journal, 2014, 29 (04) : 197 - 203
  • [42] A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
    Eriksen, Martina
    Pfeiffer, Per
    Rohrberg, Kristoffer Staal
    Yde, Christina Westmose
    Petersen, Lone Norgard
    Poulsen, Laurids Ostergaard
    Qvortrup, Camilla
    BMC CANCER, 2022, 22 (01)
  • [43] Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study
    Gallois, C.
    Elez Fernandez, M. E.
    Auclin, E.
    Bergen, E. S.
    Pernot, S.
    Higue, J.
    Trouilloud, I.
    Touchefeu, Y.
    Turpin, A.
    Mazard, T.
    Pilla, L.
    Cuissy, S.
    Wookey, V.
    Perret, A.
    Melchior, C.
    Artru, P.
    Stintzing, S.
    Dubreuil, O.
    Tougeron, D.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S446 - S446
  • [44] A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
    Martina Eriksen
    Per Pfeiffer
    Kristoffer Staal Rohrberg
    Christina Westmose Yde
    Lone Nørgård Petersen
    Laurids Østergaard Poulsen
    Camilla Qvortrup
    BMC Cancer, 22
  • [45] Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).
    Planchard, David
    Groen, Harry J. M.
    Kim, Tae Min
    Rigas, James R.
    Souquet, Pierre Jean
    Baik, Christina S.
    Barlesi, Fabrice
    Mazieres, Julien
    Quoix, Elisabeth A.
    Curtis, C. Martin
    Mookerjee, Bijoyesh
    Bartlett-Pandite, Arundathy N.
    Tucker, Christine
    D'Amelio, Anthony
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] What is the role of the anti-angiogenic therapy in BRAF (V600E) mutant metastatic colorectal cancer patients in a real-world setting?
    Martinez Lago, Nieves
    Covela Rua, Marta
    Brozos Vazquez, Elena
    Fernandez Montes, Ana Fernandez
    De la Camara Gomez, Juan Cruz
    Mendez Mendez, Carlos
    Jorge Fernandez, Monica
    Cousillas Castineira, Antia
    Grana Suarez, Begona
    Quintero Aldana, Guillermo Alfonso
    Candamio Folgar, Sonia
    Salgado Fernandez, Mercedes
    Pellon Augusto, Maria Luz
    Gonzalez Villarroel, Paula
    Gallardo Martin, Elena
    Carmona Campos, Marta
    Vazquez Rivera, Francisca
    Grande Ventura, Carlos
    Carral Maseda, Alberto
    Reboredo Lopez, Margarita
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [47] Influence of sex on safety and efficacy in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with encorafenib-cetuximab plus /-binimetinib (E-C plus /-B)
    Montana, F. J. Ros
    Navarro, V.
    Comas, R.
    Rodriguez, A. Garcia
    Gomez, D.
    Gonzalez, N. Saoudi
    Vicente, P.
    Cuadra, J. L.
    Paez, D.
    Alonso, V.
    Martinez, A. Hernandez
    Valbuena, D. E. Lopez
    Argota, I. Baraibar
    Ballabrera, F. Salva
    Tabernero, J.
    Fernandez, M. E. Elez
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S707 - S707
  • [48] BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
    Colle, Raphael
    Lonardi, Sara
    Cachanado, Marine
    Overman, Michael J.
    Elez, Elena
    Fakih, Marwan
    Corti, Francesca
    Jayachandran, Priya
    Svrcek, Magali
    Dardenne, Antoine
    Cervantes, Baptiste
    Duval, Alex
    Cohen, Romain
    Pietrantonio, Filippo
    Andre, Thierry
    ONCOLOGIST, 2023, 28 (09): : 771 - 779
  • [49] Cetuximab every second week in combination with daily encorafenib in patients with BRAF V600E mutated metastatic colorectal cancer: Interim analysis from NEW BEACON.
    Eriksen, Martina
    Pfeiffer, Per
    Rohrberg, Kristoffer Staal
    Yde, Christina Westmose
    Petersen, Lone Norgard
    Poulsen, Laurids
    Qvortrup, Camilla
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 153 - 153
  • [50] BEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)
    Huijberts, S.
    Schellens, J. H. M.
    Elez, E.
    Cuyle, P-J.
    Van Cutsem, E.
    Yaeger, R.
    Fakih, M.
    Montagut, C.
    Peeters, M.
    Desai, J.
    Yoshino, T.
    Ciardiello, F.
    Wasan, H.
    Grothey, A.
    Maharry, K.
    Gollerkeri, A.
    Kopetz, S.
    ANNALS OF ONCOLOGY, 2017, 28
12345